BRIEF: Dendreon Down Sharply in the After-Hours (DNDN)

Shares of Dendreon Corp.

ended the session off 3.75%, trading at $32.33, but have since cratered in the after-hours trade. The biotechnology company is currently trading at $27.00, off another 16.50%. Dow Jones is reporting that Medicare is probing into their “coverage” of Provenge (Dendreon’s major prostate cancer drug) to see if it is “reasonable.” Dendreon Corporation is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may improve cancer treatment options for patients. The company's product portfolio includes active cellular immunotherapy and small molecule product candidates to treat a range of cancers. Learn how to find the best

for free.